标题
PTEN loss correlates with T cell exclusion across human cancers
作者
关键词
-
出版物
BMC CANCER
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-04-19
DOI
10.1186/s12885-021-08114-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer
- (2020) Romualdo Barroso-Sousa et al. CLINICAL CANCER RESEARCH
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
- (2019) Jason J. Luke et al. CLINICAL CANCER RESEARCH
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Targeting the PI3-kinase pathway in triple-negative breast cancer
- (2019) J Pascual et al. ANNALS OF ONCOLOGY
- PTEN‐deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells
- (2019) Thiago Vidotto et al. PROSTATE
- Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma
- (2019) Weiyi Peng et al. CLINICAL CANCER RESEARCH
- PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer
- (2019) Chao Wang et al. FASEB JOURNAL
- Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
- (2019) Nicolas Guibert et al. LUNG CANCER
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
- (2018) Marco Bezzi et al. NATURE MEDICINE
- The functions and regulation of the PTEN tumour suppressor: new modes and prospects
- (2018) Yu-Ru Lee et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- (2018) Catherine S. Grasso et al. Cancer Discovery
- PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance
- (2018) Luke Russell et al. Nature Communications
- Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
- (2017) Suzanne George et al. IMMUNITY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer
- (2017) Naiyer A. Rizvi et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers
- (2016) Marie-Caroline Dieu-Nosjean et al. IMMUNOLOGICAL REVIEWS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
- (2016) R. F. Sweis et al. Cancer Immunology Research
- Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results
- (2015) Mumtahena Rahman et al. BIOINFORMATICS
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
- (2014) Alberto Toso et al. Cell Reports
- Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State
- (2012) Isabel Garcia-Cao et al. CELL
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network
- (2011) Haoqiang Ying et al. Cancer Discovery
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- (2011) Craig H Mermel et al. GENOME BIOLOGY
- Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma
- (2010) James S. Waldron et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Tenets of PTEN Tumor Suppression
- (2008) Leonardo Salmena et al. CELL
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
- The role of PTEN signaling perturbations in cancer and in targeted therapy
- (2008) M Keniry et al. ONCOGENE
- Understanding PTEN regulation: PIP2, polarity and protein stability
- (2008) N R Leslie et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started